(Q62033090)

English

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

scientific article published in May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

multicenter clinical trial

1 reference

based on heuristic

inferred from title

multiple sclerosis

1 reference

based on heuristic

inferred from title

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

Krzysztof Selmaj

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Xavier Montalban

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

2

object named as

Ralf Gold

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Eva Havrdova

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Ernst-Wilhelm Radue

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Dusan Stefoski

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Manjit McNeill

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Lakshmi Amaravadi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Marianne Sweetser

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Jacob Elkins

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Gilmore O'Neill

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Gavin Giovannoni

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

SELECTION Study Investigators

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

19 March 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Lancet Neurology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

472-481

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Normalized accurate measurement of longitudinal brain change.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Autoimmune hepatitis and multiple sclerosis: a coincidental association?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Unmasking Autoimmune Hepatitis Under Immunomodulatory Treatment of Multiple Sclerosis-not only Beta Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970039-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70039-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24656609%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q62033090&oldid=1525068537"